Q32 Bio director granted 23,272 stock options

Rhea-AI Filing Summary

Q32 Bio director Kathleen LaPorte reported a new stock option grant. On 01/15/2026, she received a stock option to buy 23,272 shares of Q32 Bio Inc. common stock with a $3.60 exercise price, under the 2024 Stock Option and Incentive Plan and the non-employee director compensation policy.

The option vests in four equal quarterly installments on the last day of each calendar quarter, as long as she continues serving as a director. LaPorte elected to receive stock options instead of cash retainer fees, and the company notes this award was initially omitted from prior reports due to administrative oversight.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LAPORTE KATHLEEN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	23,272	$2.75	$64K

Holdings After Transaction: Stock Option (Right to Buy) — 23,272 shares (Direct)

Footnotes (1)

1. F1. This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported.

FAQ

What insider transaction did Q32 Bio (QTTB) report for Kathleen LaPorte?

Q32 Bio reported that director Kathleen LaPorte received a stock option grant for 23,272 shares. The option was awarded on January 15, 2026 under the 2024 Stock Option and Incentive Plan as part of the company’s non-employee director compensation policy in lieu of cash fees.

What are the key terms of the Q32 Bio (QTTB) stock option granted to Kathleen LaPorte?

The reported stock option covers 23,272 shares of Q32 Bio common stock with a $3.60 exercise price. It was granted pursuant to the 2024 Stock Option and Incentive Plan and the non-employee director compensation policy, reflecting LaPorte’s choice to receive options instead of a cash retainer.

How does the Q32 Bio (QTTB) director stock option for Kathleen LaPorte vest?

The stock option granted to director Kathleen LaPorte vests in four equal quarterly installments. Vesting occurs on the last day of each calendar quarter and is conditioned on her continued service as a director through each applicable vesting date, according to the company’s disclosure.

Why was the Q32 Bio (QTTB) stock option grant to Kathleen LaPorte reported now?

Q32 Bio stated the option award was initially not reported due to administrative oversight. The Form 4 now records the January 15, 2026 grant of 23,272 stock options to director Kathleen LaPorte, providing an updated and accurate reflection of her reported derivative holdings.

Is the Q32 Bio (QTTB) stock option for Kathleen LaPorte held directly or indirectly?

The filing identifies the 23,272 stock options as directly owned by Kathleen LaPorte. The ownership form is marked as direct, and no footnotes indicate that the options are held through a trust, LLC, partnership, or other indirect entity in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 07:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAPORTE KATHLEEN

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.6	01/15/2026		A		23,272		(1)	01/14/2036	Common Stock	23,272	$2.75(1)	23,272	D

Explanation of Responses:

1. This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported.

	/s/ Eric Bell, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.